Cite
HARVARD Citation
Santagostino, E. et al. (2019). Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial. Thrombosis research. pp. 13-19. [Online].